Transforming Cancer Diagnoses and Treatment with Bristol Myers Squibb CDTO Greg Meyers

On the 69th episode of Enterprise AI Innovators, hosts Evan Reiser (CEO and co-founder, Abnormal AI) and Saam Motamedi (General Partner, Greylock Partners) are joined by Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. Bristol Myers Squibb is one of the top ten pharmaceutical companies, with about 30,000 employees and roughly 45 billion dollars in annual revenue, making specialty medicines in oncology, immunology, and neurology. Greg shares how BMS puts commercially scalable AI products in front of doctors, why a science company had to start thinking like a data company, and how a small-team accelerator de-risks ambitious AI bets in a highly regulated industry.

Quick Hits from Greg:

On thinking like a data company: "to models, negative results matter as much as positive results."

On running small experimental teams: "making them too small to fail in a public or embarrassing way was really important."

On what really gates AI adoption: "psychology and sociology trump technology every time."

Like what you hear? Leave us a review and subscribe to the show on Apple, Spotify, and YouTube.

Enterprise AI Innovators is a show where top technology executives share specific ways AI changes how work gets done in the enterprise.

Find more great insights from technology leaders and enterprise software experts at https://www.enterprisesoftware.blog/

Enterprise AI Innovators is produced by Abnormal Studios.